PARP Inhibitors in Breast and Ovarian Cancer
Cancers · 18.04.2023 · 15 (8) · 2357
DOI: 10.3390/cancers15082357 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 18.04.2023. Verfasst von Samuel S Y Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Tan Tock Seng Hospital, Singapore 308433, Singapore. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 109 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CSCS-LKC-NHG, National Health Group-Lee Kong Chian, NHG-LKCMedicine Clinician-Scientist Career Scheme (CSCS).
Abstract (Originalsprache)
Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most successful examples of clinical translation of targeted therapies in medical oncology, and this has been demonstrated by their effective management of BRCA1/BRCA2 mutant cancers, most notably in breast and ovarian cancers. PARP inhibitors target DNA repair pathways that BRCA1/2-mutant tumours are dependent upon. Inhibition of the key components of these pathways leads to DNA damage triggering subsequent critical levels of genomic instability, mitotic catastrophe and cell death. This ultimately results in a synthetic lethal relationship between BRCA1/2 and PARP, which underpins the effectiveness of PARP inhibitors. Despite the early and dramatic response seen with PARP inhibitors, patients receiving them often develop treatment resistance. To date, data from both clinical and preclinical studies have highlighted multiple resistance mechanisms to PARP inhibitors, and only by understanding these mechanisms are we able to overcome the challenges. The focus of this review is to summarise the underlying mechanisms underpinning treatment resistance to PARP inhibitors and to aid both clinicians and scientists to develop better clinically applicable assays to better select patients who would derive the greatest benefit as well as develop new novel/combination treatment strategies to overcome these mechanisms of resistance. With a better understanding of PARP inhibitor resistance mechanisms, we would not only be able to identify a subset of patients who are unlikely to benefit from therapy but also to sequence our treatment paradigm to avoid and overcome these resistance mechanisms.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology, Tan Tock Seng Hospital, Singapore 308433, Singapore.
- Molecular Diagnostic Laboratory, Tan Tock Seng Hospital, Singapore 308433, Singapore.
ORCID-Profile: Samuel S Y Wang, Heong Valerie Yue Ming
Förderung
- CSCS-LKC-NHG
- National Health Group-Lee Kong Chian, NHG-LKCMedicine Clinician-Scientist Career Scheme (CSCS)
Zitieren
APA
Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L., & Ming, H. V. Y. (2023). PARP Inhibitors in Breast and Ovarian Cancer. Cancers, 15(8), 2357. https://doi.org/10.3390/cancers15082357
Vancouver
Wang SSY, Jie YE, Cheng SW, Ling GL, Ming HVY. PARP Inhibitors in Breast and Ovarian Cancer. Cancers. 2023;15(8):2357. doi:10.3390/cancers15082357
BibTeX
@article{Wang2023,
author = {Wang, Samuel S Y and Jie, Yeo Ee and Cheng, Sim Wey and Ling, Goh Liuh and Ming, Heong Valerie Yue},
title = {PARP Inhibitors in Breast and Ovarian Cancer},
journal = {Cancers},
year = {2023},
volume = {15},
number = {8},
pages = {2357},
doi = {10.3390/cancers15082357}
}
EUVIMED